J
James T. Symanowski
Researcher at Carolinas Healthcare System
Publications - 149
Citations - 5423
James T. Symanowski is an academic researcher from Carolinas Healthcare System. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 24, co-authored 121 publications receiving 4733 citations. Previous affiliations of James T. Symanowski include Carolinas Medical Center & Eli Lilly and Company.
Papers
More filters
Journal ArticleDOI
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang,James J. Rusthoven,James T. Symanowski,Claude Denham,E. Kaukel,Pierre Ruffié,Ulrich Gatzemeier,Michael Boyer,Salih Emri,Christian Manegold,Clet Niyikiza,Paolo Paoletti +11 more
TL;DR: Treatment with pemetrexed plus cisplatin and vitamin supplementation resulted in superior survival time, time to progression, and response rates compared with treatment with cis Platin alone in patients with malignant pleural mesothelioma.
Journal ArticleDOI
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma
Giorgio V. Scagliotti,Dong-M. Shin,Hedy L. Kindler,Michael J. Vasconcelles,Uwe Keppler,Christian Manegold,Howard A. Burris,Ulrich Gatzemeier,J. Blatter,James T. Symanowski,James J. Rusthoven +10 more
TL;DR: It is indicated that patients with MPM could benefit from single-agent pemetrexed treatment combined with vitamin supplementation and patients supplemented with folic acid and vitamin B12 tolerated treatment better and had a 5-month greater median overall survival than nonsupplemented patients.
Journal ArticleDOI
PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer
R. Wendel Naumann,Robert L. Coleman,Robert A. Burger,Edward A. Sausville,Elzbieta Kutarska,Sharad A. Ghamande,Nashat Y. Gabrail,Stephen E. DePasquale,Elżbieta Nowara,Lucy Gilbert,Robert H. Gersh,Michael Teneriello,Wael A. Harb,Panagiotis A. Konstantinopoulos,Richard T. Penson,James T. Symanowski,Chandra D. Lovejoy,Christopher P. Leamon,David Morgenstern,Richard A. Messmann +19 more
TL;DR: Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer.
Journal ArticleDOI
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
Claire S. Zhu,Paul F. Pinsky,Daniel W. Cramer,David F. Ransohoff,Patricia Hartge,Ruth M. Pfeiffer,Nicole Urban,Gil Mor,Robert C. Bast,Lee E. Moore,Anna Lokshin,Martin W. McIntosh,Steven J. Skates,Allison F. Vitonis,Zhen Zhang,David C. Ward,James T. Symanowski,Aleksey Lomakin,Eric T. Fung,Patrick M. Sluss,Nathalie Scholler,Karen H. Lu,Adele Marrangoni,Christos Patriotis,Sudhir Srivastava,Saundra S. Buys,Christine D. Berg +26 more
TL;DR: A multisite systematic evaluation of biomarker panels using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) screening trial found a pattern where a model derived from all 28 markers failed to show improvement over CA125.
Journal ArticleDOI
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma
Christian Manegold,James T. Symanowski,U. Gatzemeier,Martin Reck,J. von Pawel,C. Kortsik,Kristiaan Nackaerts,Pilar Lianes,Nicholas J. Vogelzang +8 more
TL;DR: PSC in malignant pleural mesothelioma was significantly associated with prolonged survival and the potentially beneficial role of PSC should be assessed in prospective trials.